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Abstract  
Heparan sulfate mimetics, which we have called the PG500 series, have been developed to 
target the inhibition of both angiogenesis and heparanase activity. This series extends the 
technology underpinning PI-88, a mixture of highly sulfated oligosaccharides which reached 
Phase III clinical development for hepatocellular carcinoma. Advances in the chemistry of the 
PG500 series provide numerous advantages over PI-88. These new compounds are fully 
sulfated, single entity oligosaccharides attached to a lipophilic moiety, which have been 
optimized for drug development. The rational design of these compounds has led to vast 
improvements in potency compared to PI-88, based on in vitro angiogenesis assays and in vivo 
tumor models. Based on these and other data, PG545 has been selected as the lead clinical 
candidate for oncology and is currently undergoing formal preclinical development as a novel 
treatment for advanced cancer.  
Introduction
It is now widely recognized that tumors are critically dependent on angiogenesis [1, 2], i.e. the 
growth of new blood vessels from those already surrounding a tumor. Thus, the inhibition of 
angiogenesis has become an important therapeutic strategy for cancer [3]. Cell 
surface/extracellular matrix (ECM) heparan sulfate (HS) glycosaminoglycans are complex 
polysaccharides that are ubiquitous in nature and play important roles in the regulation of several 
aspects of cancer biology, including angiogenesis, tumor progression and metastasis [4, 5]. Several 
growth factors, their receptors, extracellular matrix molecules and enzymes bind to specific sites 
on the HS sugar chain to facilitate cellular and biochemical responses. HS mimetics function by 
blocking these interactions and inhibiting processes crucial to tumor progression and is therefore a 
promising approach for new cancer therapeutics [4, 6, 7]. This has been illustrated by the sulfated 
oligosaccharide PI-88, which reached Phase III clinical development for hepatocellular carcinoma. 
The PG500 series represents a collection of new HS mimetics based on anomerically pure, fully 
sulfated, mono-, di-, tri-, tetra- and pentasaccharide glycosides modified by the addition of an 
aglycon at the non-reducing end of the molecule. The aglycones are primarily lipophilic groups 
chosen specifically to improve the biological activities, for example efficacy and pharmacokinetic 
properties. PG500 series compounds are believed to interfere with two important processes in 
tumor development, namely angiogenesis via inhibition of vascular endothelia growth factor 
(VEGF), fibroblast growth factor-1 (FGF-1), fibroblast growth factor-1 (FGF-2) and metastasis, 
via inhibition of heparanase activity. The recent discovery that heparanase acts as a signaling 
molecule for VEGF induction [8] and induces VEGF-C to facilitate tumor lymphangiogenesis [9] 
also implicates heparanase in the development of tumor vascularization. Furthermore, enhanced 
heparanase expression in human tumors correlates with metastatic potential, tumor vascularity and 
reduced postoperative survival of cancer patients, attributed to enzymatic and nonenzymatic 
activities of the heparanase protein. Urinary and plasma levels of heparanase are elevated in cancer 
patients and suppressed in response to effective anticancer treatments. Thus, the enzyme is a 
promising target for anticancer drug development [10]. 
This study illustrates the improvements in biological activity that was observed during the 
discovery phase of the PG500 series program to design a HS mimetic. Ultimately, this has led to 
the emergence of a series of compounds that may be classified as new chemical entities (NCE’s) 
on a single carbon backbone with potent anti-angiogenic, anti-metastatic and antitumor activity. 
This is due to the dual mode of action as a heparanase inhibitor and an angiogenesis inhibitor with 
low anti-coagulant activity in comparison to PI-88 or heparin. 
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Material and Methods 
Cell lines, cell culture, reagents and compounds 
Human umbilical vein endothelial cells (HUVEC) were maintained in EBM-2 media 
supplemented with 2% FBS and Singlequots™ (Lonza, Walkersville, MD). HT29 tumor cells 
were cultured in RPMI1640 cell culture medium (Invitrogen, Mt Waverley, Australia), foetal 
bovine serum (Invitrogen), penicillin/streptomycin (Sigma-Aldrich, Castle Hill, Australia) at 
vivoPharm Pty, Australia. B16 tumor cells were cultured in DMEM - High Glucose (Gibco, Mt 
Waverley, Australia), 10% foetal bovine serum (Hyclone, Logan, UT, USA) and 1x 
Penicllin/Streptomysin/Glutamine (Gibco) at the Diamantina Institute, University of Queensland, 
Australia. PG500 series compounds were synthesized by Progen Pharmaceuticals Ltd. and 
dissolved using phosphate buffered saline (PBS), pH 7.2 and stored at 4oC for the duration of each 
experimental period. 
BIAcore binding assays 
Binding affinities of ligands binding at the HS-binding site of the growth factors FGF-1, FGF-2 
and VEGF were measured using a surface plasmon resonance solution affinity assay performed on 
a BIAcore 3000 (BIAcore, Uppsala, Sweden) operated using the BIAcore Control Software, as 
previously described [11, 12]. 
Anticoagulant Assays 
The anticoagulant activity of these compounds was investigated using the activated partial 
thromboplastin time or APTT test (which assesses effects on the intrinsic coagulation pathway), 
and the Heptest (which assesses the inhibition of exogenous Factor Xa by plasma Antithrombin 
III). Both tests were conducted in the laboratory of Job Harenberg, University of Mannheim, 
Germany according to conventional medical laboratory protocols. 
Fondaparinux Heparanase assay 
Heparanase activity was determined by measuring the cleavage of fondaparinux [13]. The newly 
formed reducing disaccharide can be detected by reacting with the mono-tetrazolium salt WST-1 
(Auspep, Melbourne, Australia). Recombinant human heparanase was expressed in insect cells 
[14]. Assays were set up in a volume of 100 µL comprising 40 mM sodium acetate buffer, pH 5.0, 
100 µM Fondaparinux and varying concentrations of inhibitor in 96 well plates (Costar 9018, 
Corning) pre-coated with BSA. Purified recombinant heparanase (2.55 nM) was then added to start 
the assay. The plate was incubated at 37 oC for 24 h and the assay stopped by the addition of WST­
1 solution (100 µL of 1.69 mM WST-1 in 0.1 M NaOH). After sealing the plates with adhesive 
film, reaction of the product disaccharide with WST-1 occurred at 60 oC for 60 min. The 
absorbance was then measured at 584 nm using a microplate reader (Fluostar, BMG) and the 
amount of product disaccharide quantified using D-galactose as standard. D-galactose was shown 
to yield the same absorbance on a per molar basis when reacted with WST-1 as the product 
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disaccharide. The IC50 value for each compound was determined and converted to a Ki using 
Cheng and Prusoff, 1973 [15] and the Km of heparanase for fondaparinux, which was determined 
to be 33 + 6 µM. 
Growth factor-induced endothelial cell proliferation assay 
Growth factor-induced endothelial cell proliferation using either HUVECs or dHMVECs was 
induced using FGF-1, FGF-2 or VEGF in the absence or presence of various concentrations of 
PG500 series compounds ranging from 0.01-50µM, depending on the individual experiment. 
5Briefly, 100µL cells at a concentration of 2x10 /µL, 50µL of growth factor (typically 10ng/mL for 
FGF-2 and VEGF and 25ng/mL for FGF-1) and 50µL of medium or PG500 series compounds 
were added to each well for 72 hours. Twenty microlitres of the CellTitre 96™ Aqueous One 
Solution Cell Proliferation Assay (Promega) was added for the final 2-4h prior to reading the 
absorbance at 490nm to obtain OD values. Once these values were subtracted from the blanks 
(media only), the data was imported into BIACORE software to determine the IC50 values for each 
curve. IC50 values have been measured to indicate the inhibitory effect of each compound on either 
FGF1-, FGF2- or VEGF-induced endothelial cell proliferation. 
Tube formation assay 
HUVECs in the fourth or fifth passage at 70-80% confluence were harvested and resuspended in 
Clonetics endothelial growth medium (EGM2) containing all supplements as directed by 
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manufacturer, except heparin, at a cell density of 4 x 10 cells per mL. For each set of triplicate 
5wells, 200µL of cells (4x10 /mL) were treated with an equal volume of compound to obtain final 
concentrations of 10, 50 or 100µM. A 100µL aliquot of cells was then plated onto 96-well plates 
precoated with growth factor reduced Matrigel™ (BD Biosciences, San Jose, CA) and incubated 
for 18-22 h. Tube formation was examined by phase-contrast microscopy and images were 
collected using an Olympus C5050 digital camera. Tube formation inhibition was quantitated 
manually from images by recording the total number of nodes connecting 3 or more tubules. 
Results are expressed as percentage inhibition compared to control. Untreated HUVECs were used 
as a control for normal cell growth and tube formation in Matrigel™. 
Rat aortic assay for angiogenesis 
The rat aortic assay was performed using a modified protocol of the method originally described 
[16]. Briefly, 180µL of Matrigel™ (BD Biosciences) was pipetted into 48-well tissue culture 
plates (Nunc). The plates were incubated at 37oC for 30 minutes to allow Matrigel™ to solidify. 
Aortic segments were placed on top on the Matrigel™ in the centre of each well before being 
sealed with an additional 60µL of Matrigel™. Each well was supplemented with 1mL media 
containing control or PG500 series compounds at concentrations of 1, 10 and/or 50µM. Media was 
replenished every 24h and on day 6 microvessels were scored using two assessors and employing a 
scoring system from 0-5 where 0 = no microvessels to 5 = diffuse angiogenesis as previously 
described [17]. In some experiments, the viability of the tissue was assessed following treatment 
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with a compound by washing out compound and adding complete media with VEGF (10ng/mL) 
for an additional 72h. 
Tumor models 
HT29 colorectal cells were grown to no more than 70-80% confluency prior to harvest. Adherent 
cells were harvested by trypsinisation and washed in HBSS. Following a total of three washes, the 
cells were resuspended in HBSS and adjusted to a final cell concentration of 2 x 107/mL. Prior to 
inoculation the injection site, on the dorsal right flank, was liberally swabbed with alcohol and 
6100µL of cells (2 x10 cells) were injected. The treatment of mice commenced with an average 
3tumor volume of approximately 155mm . Tumors were measured in two dimensions (length and 
3width) and the tumor volume (mm ) calculated using the equation: 
2V = length × width × π/6 
B16 melanoma cells were grown to no more than 70-80% confluency prior to harvest. Adherent 
cells were harvested using EDTA and washed in HBSS. Following a total of three washes, the 
6cells were resuspended in HBSS and adjusted to a final cell concentration of 5 x 10 /mL. Prior to 
inoculation the injection site, on the neck scruff, was liberally swabbed with alcohol and 100µL of 
5cells (5 x10 cells) were injected subcutaneously for the solid tumor studies. For the experimental 
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metastasis model, the final cell concentration was 2 x 10 /mL and 100µL of cells (2 x10 cells) 
were injected intravenously via tail vein injection (Day 0). Treatment in the experimental 
metastasis model commenced on Day 0, or in the solid tumor model, on Day 3 following tumor 
cell inoculation. Compounds were injected via the subcutaneous route in a volume of injection of 
100µL PBS at doses stated in figure legends. Clinical observation was performed daily to monitor 
the animals’ health and bodyweight measurements taken throughout the study. 
Statistical Analysis 
Data from the B16 melanoma metastatic model was analyzed by a one-way analysis of variance 
(ANOVA) followed by a post hoc Dunnett’s test (Graphpad Instat, v3.0). Data are presented as 
mean ± SEM. Differences with a p value of less than 0.05 were considered statistically significant. 
Data from the HT29 xenograft model were analyzed by ANOVA (all pairwise multiple 
comparison procedure and multiple comparison versus control group – Holm-Sidak Method) using 
SigmaStat v3.0.A p value of less than 0.05 was considered significant. 
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Results
The compounds were assessed initially for their affinity for the angiogenic growth factors FGF-1, 
FGF-2, and VEGF, and for their ability to inhibit heparanase activity (Table 1). The PG500 
compounds show high affinity for the growth factors in the BIAcore assays although the affinities 
are generally lower than the values observed for PI-88. This is most likely a consequence of the 
lipophilic aglycones and their ability to influence the binding properties of these compounds. 
Nonetheless, these findings were critical as they provided confirmation that the essential chemical 
alterations on the carbohydrate portion of each compound did not adversely affect the heparan 
mimetic properties of these agents. Importantly, it also became evident that most PG500 series 
compounds, particularly those containing a larger lipophilic moiety, had lower APTT and Heptest 
results, thus reducing the anticoagulant activity compared to PI-88. 
Table 1: Binding Affinities (Kd, nM), Heparanase Inhibition (Ki, nM), and Anticoagulant Activity 
(seconds) of Selected PG500 Series Compounds. 
Compound Kd (nM) Ki (nM) Anticoagulant Activity 
FGF-1 FGF-2 VEGF Heparanase APPT Heptest 
(0.1mg/mL) (0.1mg/mL) 
PG517 0.4 129 21 162 418 281 
PG518 0.2 160 18 59 97 79 
PG536 0.6 160 22 6 94 28 
PG537 0.4 108 40 6 68 24 
PG545 8.0 390 29 6 71 29 
PG546 9.7 390 95 4 104 46 
PG547 50.0 610 790 16 61 30 
PG554 24.8 547 190 9 52 29 
PG561 32.2 530 380 11 51 25 
PG562 4.9 311 14 9 66 32 
PI-88 0.2 95 2 8 >500 >500 
The biological benefits of the PG500 series really became apparent in cell-based screens employed 
to mimic various processes involved in angiogenesis, presumably due to the introduction of the 
lipophilic moieties in the molecules. The first of these assays focuses on the ability of these 
compounds to inhibit the proliferation of endothelial cells in response to angiogenic growth 
factors. The selected PG500 series compounds all inhibited FGF1, FGF2 and VEGF-induced 
endothelial cell proliferation using HUVECs (Figure 1). The IC50 values of some PG500 series 
compounds (e.g. PG545) in growth factor-induced HUVEC proliferation assays are up to 
approximately 20-fold (for FGF-2) or 40-fold (for FGF-1 and VEGF) lower compared to PI-88. 
The second model, the tube formation assay, considers the ability of the compounds to disrupt 
endothelial cell organization and in vitro angiogenesis [18]. In this assay, a number of PG500 
series compounds (PG536, PG537, PG545, and PG562) inhibited tube formation over 90% at 
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10µM (Figure 2a). At this concentration, the inhibition by these compounds has been significantly 
improved compared with PI-88 and earlier compounds in the series such as PG517 or PG518 [19]. 
Figure 2b illustrates the relative potencies of PG517 and PG545 at 10µM compared to vehicle. A 
third cell-based model, the rat aortic assay for angiogenesis, is a well known ex vivo assay for the 
testing of putative anti-angiogenic agents [18]. The most potent compounds in this model emerged 
as PG536, PG545 and PG546, all inhibiting angiogenesis over 80% when administered daily at 
10µM for 6-8 days (Figure 3a). This potent inhibition by compounds such as PG545 and PG546 is 
illustrated in Figure 3b. Although PI-88 inhibits up to 60% at 10µM, increasing the concentration 
up to 50µM did not lead to greater inhibition (data not shown). In studies which assessed tissue 
viability following 6 days of treatment with PG500 series compounds, microvessels emerged in 
most cultures treated with VEGF for 72 hours (data not shown), indicating that the compounds do 
not induce a toxic effect on the tissue. 
To demonstrate the effectiveness of these agents in tumor models, we selected one experimental 
metastatic model (B16 melanoma), previously found to be responsive to PI-88 treatment, and two 
solid tumor models that previously demonstrated resistance to PI-88 treatment. The B16 
melanoma model is a syngeneic mouse model which was employed as the first in vivo screen by 
the inoculation of tumor cells via an intravenous route for the experimental metastasis model or 
subcutaneously for the solid tumor model. In both models, PG500 compounds were dosed for 
twelve consecutive days. As shown in Figure 4a, selected compounds in this test PG545, PG546 
and PG547, potently inhibited the development of metastatic nodules when administered at 
10mg/kg. The reduction in the number of metastatic nodules on the lung by treatment with PG545 
is exemplified by Figure 4b. Previously, it was found that 30mg/kg daily treatment with PI-88 also 
led to similar findings in this model (Figure S1, supplementary data). In the solid tumor B16 
model (resistant to PI-88), tumor development during the treatment period was potently inhibited 
by the selected compounds PG545, PG546 and PG547 (Figure 5a). Of these compounds 
demonstrating efficacy, PG545 was selected for further testing in a xenograft model (HT29 colon) 
and found to significantly inhibit the tumor development compared to saline control (Figure 5b). 
In addition, the chemotherapeutic agent 5-fluorouracil (5-FU) was also used as a positive control 
in the study. 
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Discussion
This study details the rationale for the development of a new series of potent heparan sulfate 
mimetics; collectively known as the PG500 series. In a distinct departure from PI-88 from which 
they owe their parentage, the candidate compounds are now fully synthetic and fully sulfated 
single entities that exhibit potent antitumor properties comparable to or better than PI-88 or other 
known sulfated polysaccharides (e.g. heparin). For these reasons outlined above, further 
development of compounds, particularly PG545, is currently underway. 
BIAcore binding data, which probes for HS binding site activity, indicated low nanomolar binding 
of PG500 series compounds to HS-binding proteins FGF1, FGF2 and VEGF which are important 
in tumor angiogenesis. The potency with which these compounds inhibit the activity of 
heparanase, which is critical for the remodeling of the extracellular matrix, extends the potential 
use of these compounds. The real departure in this technology becomes apparent, however, in cell-
based assays where, particularly the later compounds in the series, potently inhibit growth factor-
induced endothelial cell proliferation - the first important cellular process in angiogenesis. The 
effects of the PG500 series on subsequent processes in angiogenesis have been studied by the tube 
formation assay and the rat aortic assay for angiogenesis, both of which are routinely used to 
identify compounds as potent anti-angiogenic molecules. It is also important to note that the 
PG500 series compounds do not induce cytotoxicity at concentrations tested in the models 
described. For example, the lethal concentration required to kill 50% of endothelial cells (LC50) for 
PG545 is 78µM (Table S1, supplementary data) which is over 80-fold higher than its IC50 
concentration in the endothelial cell proliferation assay. Previous data indicated that PG500 series 
compounds can induce anti-angiogenic activity in in vivo models of angiogenesis [19]. 
In order to determine whether such activity would be applicable to a clinical cancer setting, we 
investigated the ability of some of these PG500 series compounds (PG545, PG564 and PG547) to 
inhibit tumour development in vivo in the B16 solid tumour and metastatic model. In the solid 
tumour model, which is resistant to PI-88, tumour development was reduced by daily 
administration of all three compounds. Further investigations will assess the duration that such an 
effect can be maintained in the presence or absence of compound. In addition, the intravenous 
injection of B16 melanoma cells via the tail vein colonize in the lungs of mice which can be 
utilized as an in vivo screen for putative anti-metastatic activity and in which PI-88 has been found 
to be active (Figure S1, supplementary data). Again, all three compounds tested significantly 
reduced the number of metastatic nodules in this model which may be indicative of a class effect 
of HS mimetics/heparanase inhibitors. A recent paper using the B16 experimental metastasis 
model found that the tyrosine kinase inhibitor sunitinib actually accelerated metastasis in all mice 
when the drug was administered 7 days prior to tumor implantation or in half the mice when 
administered for 7 days post-implantation, thus not producing a survival advantage [20]. Similar 
data was noted using an anti-VEGFR2 antibody in the RIP1-Tag2 model of pancreatic 
neuroendocrine cancer (PNET) with the authors concluding that such undesirable therapy­
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triggered change in the natural history of the treated tumors is convergent with emerging examples 
involving other targeted therapy-driven changes [21]. Based on these recent publications, the 
results with PG500 series compounds in the experimental metastasis model could prove to be a 
new ally for cancer therapy. 
PG545 was then tested in the HT29 colon xenograft model and found to significantly inhibit 
tumour development comparable with the standard of care chemotherapeutic agent 5-fluorouracil 
(5-FU). The fact that administration of these agents, and in particular PG545, to tumor-bearing 
animals led to significant tumour growth inhibition strongly supports the further development of 
these HS mimetics for the treatment of cancer. It is of interest to note that the enhanced potency of 
PG500 series compounds in in vitro angiogenesis assays provides a plausible explanation for the 
improved efficacy observed with these compounds in solid tumor models, known to be resistant to 
PI-88 treatment. Moreover, the similar effects of PG500 series compounds to PI-88 on the 
enzymatic activity of heparanase in vitro seems to correlate with the efficacy of all compounds in 
a metastatic model of melanoma. The relative role of heparanase and angiogenesis in forming a 
particular tumor microenvironment is a key field of intensive research which will likely facilitate 
the development of such drug candidates to the clinic. 
In summary, we have demonstrated that the PG500 series of heparan sulfate mimetics potently 
block the enzymatic activity of heparanase, angiogenesis and tumor development. The inhibition 
of heparanase activity is a considerably important attribute and one which will require the 
development of a sophisticated in vivo model to fully appreciate its relative contribution to the 
anti-tumor effects of these compounds. Taken together, the data demonstrates that the 
administration of these agents to tumor-bearing animals significantly reduce metastatic nodule 
formation and solid tumor development. Based on these data and other considerations associated 
with the manufacture, chemistry and biology of these compounds, PG545 has been identified as 
the lead clinical candidate for further development as a new class of anti-cancer agent. 
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Legends 
Figure 1: Concentration that inhibits 50% (IC50) values for selected PG500 series compounds in a 
growth factor - induced HUVEC proliferation assay. Enhanced anti-proliferative activity was 
particularly evident in compounds from PG536 onwards generating approximately 20-fold (for 
FGF1), 10-fold (for FGF-2) or 20-fold (for VEGF) improvements compared to PI88, the IC50 
values of which have been published elsewhere [19]. 
Figure 2: Inhibition of HUVEC tube formation by selected PG500 series compounds at 10µM 
(Figure 2a). In particular, PG536, PG537, PG545 and PG562 inhibit tube formation over 80% at 
10µM. By contrast, PI-88 at 10µM inhibits tube formation by 29% as previously reported by our 
group [19]. Some representative images of control, PG517 (10µM) and PG545 (10µM) are shown 
in Figure 2b. 
Figure 3: Inhibition of angiogenesis by selected PG500 series compounds in the rat aortic assay 
(Figure 3a). Some photomicrographs are also shown to illustrate the activity of PG545 and PG546 
in this model (Figure 3b). In some experiments designed to examine the reversibility of the 
antiangiogenic effect at the end of the treatment period (which was typically six days), aortic 
segments receiving fresh medium containing VEGF (10ng/mL) frequently developed new 
microvessels within 72 h (data not shown). 
Figure 4: PG500 series compounds significantly inhibit tumor metastases in the B16 melanoma 
model. The compounds PG545, PG546 and PG547were administered subcutaneously once daily 
for 12 days at 10 mg/kg/day after tumor cells were inoculated intravenously via tail vein injection 
at Day 0. Data expressed as mean number of metastases with SEM (Figure 4a). ** = P<0.01 versus 
control as analysed by a oneway ANOVA followed by a Dunnett’s post hoc test. An example of 
metastatic nodules in lungs from control and PG545-treated animals are shown in Figure 4b. 
Figure 5: PG500 series compounds inhibit tumor progression in solid tumor models. In the B16 
melanoma model, PG545, PG546 and PG547 were administered subcutaneously once daily for 12 
days at 15 mg/kg/day, 3 days after tumor challenge at Day 0. Potent inhibition of tumor growth 
was evident in each treatment group. In the HT29 xenograft model, PG545 was shown to 
significantly inhibit tumor development (P<0.01) when administered daily at 5mg/kg/day. Data 
expressed as mean tumor volume with SEM (Figure 4b). Statistical analysis was conducted using a 
oneway ANOVA followed by a Dunnett’s post hoc test. 
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